$ACOG.v Reports Pre-Clinical Data For ALPHA-0602 Further positive data is coming from Alpha Cognition (TSXV: ACOG) with the announcement that in a recent clinical study, its ALPHA-0602 therapy has yielded positive evidence for its use in the treatment of ALS.
This positive news regarding the ALPHA-0602 therapy adds further strength to Alpha’s product line. The company announced positive pre-clinical data for its ALPHA-1062 product in late February, supporting its efficacy as a treatment for TBI. The company is expecting approval and launch of 1062 in 2023, and the progress being made on the 0602 therapy makes for even more potential catalysts to watch for from the company this year.
$ACOG.v shares have maintained lateral movement since breaking through a bearish trend, and have shown a key price of $1.09 to watch as a line of resistance. $ACOG.v is currently trading at $.98 and is valued at $60.27M.
https://ceo.ca/@businesswire/alpha-cognition-announces-positive-data-from-pre-clinical